While “the key issue is the price” of insulin products, pharmacy benefit managers have driven discounts for consumers by creating lists of covered drugs in which some insulin products are more favorably covered than others, says Pharmaceutical Care Management Association President and CEO Mark Merritt. A resolution from the American Diabetes Association’s board of directors urges Congress to investigate why the prices of insulin — a 95-year-old drug — have risen precipitously since the mid-1990s.